Bristol Myers Squibb BMY
NYSE BMY
$62.93 -0.50 (-0.79%)
At close: Nov 16, 2026 · 4:00 PM EST

Bristol Myers Squibb (BMY) Sale and Maturity of Investments (2009 - 2026)

Updated

Bristol Myers Squibb (BMY) posted Sale and Maturity of Investments - Total of $1.05 billion for Q3 2026, up 19.4% from $878 million a year earlier and up 63.0% from the prior quarter.

Analysis

Bristol Myers Squibb (BMY) Sale and Maturity of Investments (2009 - 2026) Analysis & Trends

For the trailing twelve months through Sep 30, 2026, Sale and Maturity of Investments - Total at Bristol Myers Squibb was $2.86 billion, up 50.4% year-over-year; for FY2025, it came in at $2.05 billion, up 47.9% from FY2024.

  • Annual Sale and Maturity of Investments - Total shows a five-year compound annual growth rate of -20.4% (FY2020 to FY2025).
  • In prior years, Bristol Myers Squibb's Sale and Maturity of Investments - Total was $1.39 billion in FY2024 (+46.3%), $948 million in FY2023 (-85.7%), $6.63 billion in FY2022 (-2.2%) and $6.78 billion in FY2021 (+5.7%).
  • The Q3 2026 figure stands as the highest quarterly Sale and Maturity of Investments - Total since Q4 2022.
  • On a year-over-year basis, Sale and Maturity of Investments - Total has increased in each of the last six quarters, with growth averaging 172.0% over the last eight quarters.
  • The strongest year-over-year quarter for Sale and Maturity of Investments - Total in the past five years was Q4 2024, with growth of 551.2%; the weakest was Q4 2023, with a decline of 96.6%.
  • According to Business Quant data, Sale and Maturity of Investments - Total for the three prior quarters was $643 million (Q2 2026), $750 million (Q1 2026) and $418 million (Q4 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Investments Sold (Qtr)
1 Eli Lilly 1,276.89 Bn 1,250.50 Bn 20.46 Bn -
2 Johnson & Johnson 681.31 Bn 601.18 Bn 17.30 Bn 308.00 Mn
3 AbbVie 520.63 Bn 488.64 Bn 13.12 Bn -
4 Merck 357.22 Bn 320.16 Bn 13.19 Bn 405.00 Mn
5 Novartis Ag 310.90 Bn 284.14 Bn - 88.00 Mn
6 Astrazeneca 285.12 Bn 258.77 Bn 13.26 Bn -
7 Amgen 250.23 Bn 201.89 Bn 7.58 Bn -
8 Gilead Sciences 207.56 Bn 182.67 Bn 6.73 Bn -
9 Pfizer 164.42 Bn 111.77 Bn 12.56 Bn 2.53 Bn
10 Bristol Myers Squibb 128.63 Bn 83.82 Bn 8.92 Bn 1.05 Bn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 1.05 Bn
Jun 30, 2026 643.00 Mn
Mar 31, 2026 750.00 Mn
Dec 31, 2025 418.00 Mn
Sep 30, 2025 878.00 Mn
Jun 30, 2025 524.00 Mn
Mar 31, 2025 232.00 Mn
Dec 31, 2024 267.00 Mn
Sep 30, 2024 238.00 Mn
Jun 30, 2024 130.00 Mn
Mar 31, 2024 752.00 Mn
Dec 31, 2023 41.00 Mn
Sep 30, 2023 513.00 Mn
Jun 30, 2023 275.00 Mn
Mar 31, 2023 119.00 Mn
Dec 31, 2022 1.21 Bn
Sep 30, 2022 1.48 Bn
Jun 30, 2022 1.84 Bn
Mar 31, 2022 2.10 Bn
Dec 31, 2021 2.77 Bn
API Access

Bristol Myers Squibb Sale and Maturity of Investments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=sale-and-maturity-of-investments&ticker=BMY&period=max&api_key=YOUR_API_KEY